Stock listing

ASX:AN1 Anagenics Limited Share Price

Follow Anagenics Limited into a list and get an email when it puts out news.

Share price · ASX:AN1

$0.0060 AUD 0.0000 (0.0%)

Close on Nov 19, 2026

Past year +20.0% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.0060 – $0.0060 AUDNov 19, 2026
Market cap
$5.91M AUDAt the close on Nov 19, 2026 · price × 985.5M shares outstanding
52-week range
$0.0040 – $0.0090 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$1,209 AUDMedian day 0 shares · 34 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
Anagenics Limited logo

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:AN1 · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.0060-0.0010-14.3%$0.0070$0.0070$0.0060891,746
$0.00700.00000.0%$0.0070$0.0070$0.00700
$0.00700.00000.0%$0.0070$0.0070$0.00700
$0.0070+0.0010+16.7%$0.0070$0.0070$0.0070308,586
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00601,217,504
$0.0060+0.0010+20.0%$0.0050$0.0060$0.0050329,738
$0.00500.00000.0%$0.0060$0.0060$0.00504,425,887
$0.00500.00000.0%$0.0050$0.0050$0.0050484,377
$0.00500.00000.0%$0.0050$0.0050$0.004066,118
$0.00500.00000.0%$0.0050$0.0050$0.00505,000
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.005010,000
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.005026,000
$0.00500.00000.0%$0.0050$0.0050$0.00501,563
$0.00500.00000.0%$0.0050$0.0050$0.00502,000,000
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.0050190,675
$0.00500.00000.0%$0.0050$0.0050$0.0050250,000
$0.00500.00000.0%$0.0050$0.0050$0.0050344,673
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.0050919,384
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.0050500,000
$0.0050-0.0010-16.7%$0.0050$0.0050$0.0050500,000
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.0060328
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0050$0.0060$0.0050152,198
$0.00600.00000.0%$0.0060$0.0060$0.006010,302
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.0060375,160
$0.00600.00000.0%$0.0060$0.0060$0.0050289,066
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00602,000
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.0060120,000
$0.00600.00000.0%$0.0060$0.0060$0.0060170,833
$0.00600.00000.0%$0.0060$0.0060$0.0060470,667
$0.00600.00000.0%$0.0060$0.0060$0.00606,333
$0.00600.00000.0%$0.0070$0.0070$0.0060737,000
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.006099,550
$0.00600.00000.0%$0.0060$0.0060$0.0060149,167
$0.00600.00000.0%$0.0060$0.0060$0.005014,350
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00600
$0.00600.00000.0%$0.0060$0.0060$0.00602,663
$0.00600.00000.0%$0.0060$0.0060$0.00600

Splits

2 splits since 2017 · ASX:AN1 · every price before a split is adjusted for it

DayRatioWhat
101-for-94Split
1-for-20Consolidation
Ticker
ASX:AN1
Asset type
Stock
Sector
Consumer goods
Industry
Household & personal care
Exchange
ASX
Currency
AUD

What changed lately

Latest news

All Anagenics Limited news

Anagenics Limited on 6ix

Sector
Consumer goods
Industry
Household & personal care
News releases
20 in the last 12 months · 177 in all · newest Nov 20, 2026 · oldest 2016
Decks
38 decks · latest Feb 25, 2026

Valuation

P/E 19.2× against a median of 13.4×: the highest of 3 Household & personal care companies shown. Statements: Year to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
$5.37M AUD
P/E
19.2×
EV/sales
1.0×
EV/EBITDA
6.6×
Price/book
1.4×
Gross margin
54.5%
Operating margin
12.2%
Net margin
6.0%
Debt to equity
0.0×
Beta
No index for this market yet

Household & personal care: the 10 companies nearest in size, of 134 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Anagenics Limited · ASX:AN1US$3.91MUS$3.55M19.2×1.0×6.6×1.4×6.0%0.0×n/a
JHS Svendgaard Laboratories Limited · NSE:JHSUS$7.48MUS$8.49Mn/a0.7×29.9×0.4×−1.1%0.1×n/a
La Savonnerie de Nyons SA · EURONEXT:MLSDNUS$7.28MUS$6.24M11.2×1.3×6.6×1.9×13.5%0.2×n/a
Miraculum S.A. · GPW:MIRUS$6.97MUS$10.23Mn/a0.8×40.6×1.0×−2.0%0.5×n/a
Caring Brands, Inc. · NASDAQ:CABRUS$6.91M−US$759,746n/an/an/a0.9×n/a0.0×0.78
Eng Kah Corp. Bhd. · MYX:ENGKAHUS$5.41MUS$1.72Mn/a0.2×n/a0.5×−28.1%0.0×n/a
Sea Mild Biotechnology Co., Ltd. · TPEX:7516US$4.16MUS$2.23M15.5×0.2×2.4×1.2×2.6%0.1×n/a
CCA Industries, Inc. · OTC:CAWWUS$2.64MUS$2.93Mn/a0.6×n/a0.8×−6.8%0.1×0.08
Dermata Therapeutics, Inc. · NASDAQ:DRMAUS$2.52M−US$2.30Mn/a−31.0×n/a0.7×n/a0.0×1.22
Skin Laboratory Public Company Limited · SET:SKINUS$2.50MUS$827,978n/a0.2×n/a1.0×−12.0%0.0×n/a
Highlander Enterprise S.A. · NEWCONNECT:HERUS$2.14MUS$2.14Mn/a16.0×8.7×54.7×−194.8%0.0×n/a
Median of the othersUS$4.78MUS$2.19M13.4×0.6×8.7×0.9×−4.4%0.0×0.78

Team and board

Officers

OfficerRole
Scott GreasleyExecutive Director

Board

DirectorRole
Sandy BeardChairman
Phillip ChristopherNon-Executive Director
Scott GreasleyExecutive Director

Events

QuarterResultsShare move
Q4 2025Aug 27, 2025−16.7%
Q2 2025Feb 27, 20250.0%
Q2 2023Feb 13, 2023 · After close
Q4 2022Aug 24, 2022 · After close0.0%
Q2 2022Feb 15, 2022+4.0%
Q4 2021Aug 25, 20210.0%
Quarter to Dec 31, 2020Feb 17, 2021−7.0%

Open Events

Decks

DeckKindSlidesDate
H1 2026 Earnings PresentationEarnings12 slidesFeb 25, 2026
Shareholder Meeting (November 2025)Shareholder meeting14 slidesNov 25, 2025
FY2025 Earnings PresentationEarnings15 slidesAug 28, 2025
Q3 2025 Earnings PresentationEarnings15 slidesMay 5, 2025
Shareholder Meeting (November 2024)Shareholder meeting12 slidesNov 26, 2024
FY2024 Earnings PresentationEarnings14 slidesSeptember 2024
Investor Presentation (February 2024)Investor deck16 slidesFeb 7, 2024
Shareholder Meeting (November 2023)Shareholder meeting10 slidesNov 1, 2023
Merger or Acquisition (August 2023)Merger or acquisition12 slidesAug 22, 2023
Investor Presentation (February 2023)Investor deck27 slidesFeb 14, 2023
All 38 decks
DeckKindSlidesDate
Shareholder Meeting (December 2021)Shareholder meeting17 slidesDec 9, 2021
Cellmid — Shareholder Meeting (October 2021)Shareholder meeting18 slidesOct 22, 2021
Cellmid — Merger or Acquisition (September 2021)Merger or acquisition21 slidesSep 27, 2021
Cellmid — MarketLit Millennial and Gen Z Investor Conference 2021Conference8 slidesJul 2, 2021
Cellmid — Investor Presentation (May 2021)Investor deck22 slidesMay 3, 2021
Cellmid — Shareholder Meeting (November 2020)Shareholder meeting22 slidesNov 30, 2020
Investor Presentation (November 2020)Investor deck26 slidesNov 12, 2020
Cellmid — FY2020 Earnings PresentationEarnings21 slidesAug 27, 2020
Cellmid — FY2019 Earnings PresentationEarnings22 slidesAug 28, 2019
Cellmid — Shareholder Meeting (November 2018)Shareholder meeting18 slidesNov 8, 2018
Cellmid — Investor Presentation (October 2018)Investor deck30 slidesOct 31, 2018
Cellmid — Shareholder Meeting (September 2018)Shareholder meeting27 slidesSep 7, 2018
Cellmid — Investor Presentation (July 2018)Investor deck30 slidesJuly 2018
Cellmid — Investor Presentation (April 2018)Investor deck31 slidesApril 2018
Cellmid — FY2017 Earnings PresentationEarnings29 slidesSep 27, 2017
Cellmid — Shareholder Meeting (November 2016)Shareholder meeting28 slidesNov 21, 2016
Cellmid — Shareholder Meeting (September 2015)Shareholder meeting21 slidesSep 9, 2015
Cellmid — NSW Broker Meets Biotech (March 2015)Conference10 slidesMar 4, 2015
Cellmid — Investor Presentation (March 2014)Investor deck28 slidesMarch 2014
Cellmid — Shareholder Meeting (November 2013)Shareholder meeting21 slidesNov 22, 2013
Cellmid — Brokers Meet Biotech luncheon, Perth (September 2013)Conference25 slidesSep 18, 2013
Cellmid — Merger or Acquisition (May 2013)Merger or acquisition17 slidesMay 8, 2013
Cellmid — Shareholder Meeting (November 2012)Shareholder meeting18 slidesNov 23, 2012
Cellmid — Wholesale Investor Conference 2012Conference16 slidesNov 20, 2012
Cellmid — Shareholder Meeting (November 2010)Shareholder meeting10 slidesNov 3, 2010
Cellmid — Pharma R&D Partnering World Asia conference 2010Conference12 slidesMar 19, 2010
Medical Therapies — Shareholder Meeting (May 2009)Shareholder meeting20 slidesMay 5, 2009
Medical Therapies — Merger or Acquisition (May 2008)Merger or acquisition24 slidesMay 9, 2008

Open Decks

Financings

RaiseDateIn US dollars
Private placement of securities
Announced: private placement
Nov 12, 2026
Private placement of new shares
Announced: A$2.25M · A$0.0046 a share
Use of proceeds: Expand existing brands, pursue complementary business opportunities, retire debt, working capital and placement costs
Dec 10, 2025US$1.5M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue5.16M4.75M10.8M9.11M6.95M5.82M7.38M7.30M5.65M4.50M
Cost of revenue2.35M2.71M6.44M5.06M3.15M2.11M2.53M2.14M5.62M4.83M
Gross profit2.81M2.04M4.36M4.05M3.80M3.70M4.85M5.16M27.9K-331.4K
Research and development8.68K21.2K26.2K118.8K849.0K848.5K598.5K599.6K
Selling, general and administrative2.02M2.50M7.87M4.12M118.9K64.8K5.18M5.38M3.67M2.78M
Operating income629.8K-1.32M-7.38M-1.92M-1.60M-3.64M-4.75M-5.65M-3.26M-4.14M
Depreciation and amortization186.2K200.4K616.3K359.8K495.5K434.6K518.7K152.9K187.5K168.5K
EBITDA816.1K-1.12M-6.76M-1.56M-1.10M-3.21M-4.23M-5.50M-3.07M-3.97M
Interest expense69.2K40.5K66.3K31.8K25.0K54.8K71.3K235.0K473.3K291.2K
Income before tax308.5K-1.24M-7.28M-2.20M-1.64M-3.76M-4.82M-5.89M-3.73M-4.43M
Income tax209.0K-454.7K15245.0K89.5K24.1K2.43K35.6K
Net income308.5K-1.24M-7.49M-2.67M-3.65M-3.39M-4.91M-5.91M-3.73M-4.47M
Earnings per share, basic0.00-0.00-0.02-0.01-0.02-0.02-0.05-0.07-0.06-0.08

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents577.4K395.5K1.62M2.57M3.28M6.73M6.97M3.08M1.61M3.99M
Receivables805.4K574.8K651.5K1.09M921.3K1.80M1.87M2.29M1.03M378.3K
Inventory1.03M967.7K1.48M2.40M4.45M2.55M2.61M1.62M1.18M2.08M
Current assets2.74M1.94M3.83M6.25M8.77M11.3M11.6M7.23M4.16M6.56M
Property, plant and equipment211.2K411.6K772.8K578.3K527.3K1.50M800.2K771.0K744.7K
Goodwill1.95M1.95M1.95M3.45M3.45M
Total assets4.75M4.10M6.19M11.1M12.9M13.3M14.9M9.79M6.75M8.47M
Accounts payable315.9K1.06M1.69M724.1K502.7K682.2K839.7K685.2K603.8K680.8K
Current liabilities520.8K2.19M3.17M1.71M3.66M1.92M3.48M2.91M3.72M3.76M
Long-term debt0767.5K601.4K1.03M1.02M1.17M314.6K
Total debt33.2K848.1K772.6K654.3K1.76M1.43M1.96M1.29M3.17M2.16M
Total liabilities520.8K2.28M3.48M2.22M4.64M2.86M5.08M3.93M4.89M4.08M
Shareholders' equity4.23M1.83M2.71M8.90M8.29M10.4M9.81M5.86M1.86M4.40M
Shares outstanding743.0M469.4M399.0M266.0M211.4M142.5M105.6M82.1M60.1M55.3M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-1.07M-1.58M-1.74M-1.78M-2.53M-4.11M-4.01M-5.93M-4.40M-4.06M
Capital spending-25.0K-3-97.9K-45.4K-35.9K-22.5K-22.5K-65.7K-107.2K-35.9K
Free cash flow-1.09M-1.58M-1.84M-1.83M-2.59M-22.5K-4.01M-6.00M-4.51M-4.10M
Cash from investing-25.0K0-197.9K-1.51M-968.2K477.5K477.5K-65.7K-214.1K-35.9K
Cash from financing1.28M345.4K993.7K2.56M73.3K3.50M7.98M7.27M2.19M5.44M
Dividends paid-271.4K-54.8K-202.2K
Share buybacks-150.9K0-149.3K-271.4K0-379.0K-535.8K-114.8K-27.0K4.07M
Change in cash181.9K-1.23M-943.1K-717.8K-3.44M-243.2K3.89M1.47M-2.39M1.31M

Open Financials

Filings

FilingDateTypeFiled with
AGM UpdateNov 19, 2026Meeting noticeASX
Notices under sections 203D and 249D of the Corporations ActNov 19, 2026Other filingsASX
Application for quotation of securities - AN1Nov 15, 2026FinancingASX
Proposed issue of securities - AN1Nov 11, 2026FinancingASX
Anagenics to Acquire Bio-First Skincare BrandNov 10, 2026Acquisition or disposalASX
Sale of Intellectual Property and Earn-Out ArrangementNov 4, 2026Acquisition or disposalASX
Pause in TradingNov 4, 2026Trading halt or suspensionASX
AN1 - Appendix 4C & Activity Report for Q1 FY2027Oct 22, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 5, 2026Meeting noticeASX
AN1 FY26-Appendix-4E-Aug 28, 2026ResultsASX
All 170 filings
FilingDateTypeFiled with
AN1 - Appendix 4G JUN 2026Aug 28, 2026Other filingsASX
AN1 2026 Annual ReportAug 28, 2026Annual reportASX
Appendix 4C & Activity Report for Q4 FY2026Jul 29, 2026Quarterly reportASX
Change of AuditorJul 27, 2026Management or board changeASX
AN1 - Appendix 4C & Activity Report for Q3 FY2026Apr 27, 2026Quarterly reportASX
Anagenics - 1H FY26 Result HighlightsFeb 24, 2026ResultsASX
Appendix 4D 1H FY26 DEC 2025Feb 24, 2026Interim reportASX
Appendix 4C & Activity Report for Q2 FY2026Jan 29, 2026Quarterly reportASX
Placement of SharesDec 9, 2025FinancingASX
Trading HaltDec 7, 2025Trading halt or suspensionASX
Appendix 4C & Activity Report for Q1 FY2026Oct 30, 2025Quarterly reportASX
AN1 - FY 2025 PresentationAug 28, 2025ResultsASX
AN1 FY25-Appendix-4E-Preliminary-Final-ReportAug 27, 2025ResultsASX
Activity Report & Appendix 4C Q4 FY2025Jul 28, 2025Quarterly reportASX
YSB Bouf Haircare Continues Strong PerformanceJun 27, 2025Operations updateASX
York Street Brands Product LaunchJun 4, 2025Operations updateASX
AN1 - 3Q25 PresentationMay 4, 2025Quarterly reportASX
Reinstatement to QuotationMay 2, 2025Trading halt or suspensionASX
AN1 - Pre-reinstatement DisclosureMay 2, 2025Other filingsASX
AN1 3Q25 Activity ReportMay 1, 2025Quarterly reportASX
Appendix 4C Cash Flow ReportMay 1, 2025Quarterly reportASX
Long Term Suspended EntitiesApr 9, 2025Trading halt or suspensionASX
AN1 - 1H25 UpdateFeb 27, 2025Interim reportASX
AN1 - Appendix 4D 1H FY2025Feb 27, 2025Interim reportASX
Update on 2Q25 Activity ReportFeb 10, 2025Quarterly reportASX
Q2 F25 Activity Statement and Appendix 4CJan 31, 2025Quarterly reportASX
Restructuring Update & Resignation of DirectorOct 31, 2024Operations updateASX
Q1 F25 Activity Statement and Appendix 4COct 31, 2024Quarterly reportASX
Market UpdateOct 2, 2024Acquisition or disposalASX
Suspension from Official QuotationSep 3, 2024Trading halt or suspensionASX
Pause in TradingSep 2, 2024Trading halt or suspensionASX
FY24 4E PresentationAug 30, 2024ResultsASX
Appendix 4E and Preliminary Final ReportAug 30, 2024ResultsASX
Company Update License Partnership AnnouncementJul 23, 2024Operations updateASX
Appendix 4C Cash Flow & Activities ReportJul 23, 2024Quarterly reportASX
Midkine Antibody Licensing DealMay 24, 2024Other filingsASX
Quarterly Activities/Appendix 4C Cash Flow ReportApr 28, 2024Quarterly reportASX
Organisational ChangesMar 7, 2024Management or board changeASX
H1 FY24 Results and Corporate UpdateFeb 26, 2024ResultsASX
Appendix 4D and Half Year ReportFeb 26, 2024Interim reportASX
Investor PresentationFeb 6, 2024Other filingsASX
Completion of PlacementFeb 6, 2024FinancingASX
Appendix 4C and Quarterly Activity ReportOct 30, 2023Quarterly reportASX
Business UpdateOct 1, 2023Acquisition or disposalASX
Acquisition of Face MediGroup PresentationAug 22, 2023Acquisition or disposalASX
Anagenics to Acquire Face MediGroupAug 22, 2023Acquisition or disposalASX
FY23 Financial Performance and Business UpdateJun 27, 2023Operations updateASX
CEO AppointmentMar 28, 2023Other filingsASX
Results of Institutional Entitlement OfferFeb 15, 2023FinancingASX
Entitlement Offer and Company UpdateFeb 13, 2023FinancingASX
Corporate Update and AcquisitionDec 8, 2022Acquisition or disposalASX
Appendix 4E and FY22 Financial ReportAug 24, 2022ResultsASX
Advangen Japan Divestment and Earn-Out AgreementJul 25, 2022Acquisition or disposalASX
Appointment of Exec Director, Corporate and Trading UpdateJul 7, 2022Management or board changeASX
New Leadership Driving Business TransformationMar 15, 2022Other filingsASX
Anagenics Appoints CEOFeb 28, 2022Other filingsASX
Anagenics Board and Leadership TransitionFeb 15, 2022Other filingsASX
Second Supply Agreement for Anagenics FGF5 InhibitorsDec 23, 2021Other filingsASX
BLC Cosmetics Acquisition CompletedNov 1, 2021Acquisition or disposalASX
Investor WebinarSep 26, 2021Other filingsASX
HNG: BLC Cosmetics to merge with CellmidSep 15, 2021Other filingsASX
Cellmid to Acquire BLC Cosmetics Pty LtdSep 15, 2021Acquisition or disposalASX
Appendix 4E and FY21 Financial ReportAug 19, 2021ResultsASX
Cellmid Reports Record QVC SalesJun 16, 2021Other filingsASX
Supply Agreement for Cellmids FGF5 InhibitorsJun 8, 2021Other filingsASX
Chinese Import Permits ReceivedApr 30, 2021Other filingsASX
Agreement Signed for Sale of Lyramid LimitedApr 29, 2021Other filingsASX
Supplementary ProspectusMar 31, 2021Offer documentASX
Rights Issue Closed with Strong DemandMar 31, 2021FinancingASX
Rights Issue ProspectusMar 8, 2021FinancingASX
Rights IssueMar 7, 2021FinancingASX
Cellmid Publishes Data on Novel Proprietary FGF5 AptamerFeb 8, 2021Other filingsASX
Cellmid Receives First Order From Chinese DistributorJan 24, 2021Other filingsASX
Cellmid Signs 10 Year Chinese Distribution AgreementDec 13, 2020Other filingsASX
Growth Strategy PresentationNov 11, 2020Other filingsASX
FY20 Financial ResultsAug 27, 2020ResultsASX
Appendix 4E and FY20 Financial ReportAug 27, 2020ResultsASX
CDY Signs Agreement With Premium Salon Distributor in USAJul 28, 2020Other filingsASX
Response to ASX Aware QueryJul 9, 2020Explanation requestASX
Cellmid Signs Exclusive Agreement For Sars-Cov-2 LaboratoryJul 8, 2020Other filingsASX
Extension Of Wondfo Rapid Test Distribution AgreementJul 2, 2020Other filingsASX
Cellmid Reports on Strong QVC Sales EventJun 15, 2020Other filingsASX
Cellmid Reports on Results of The Doherty Institute TestingJun 14, 2020Other filingsASX
CDY signs Introducer Agreement to broaden product offeringJun 4, 2020Other filingsASX
Appointment of Dr Dominic Burg as Chief Operating OfficerJun 1, 2020Management or board changeASX
Cellmids Alopecia Patent Allowed in Australia and JapanApr 24, 2020Other filingsASX
Independent Test Results For The Wondfo SARS-CoV-2 TestApr 22, 2020Other filingsASX
Cellmids Shipment of SARS-CoV-2 Tests ReceivedApr 14, 2020Other filingsASX
Reinstatement to Official QuotationApr 7, 2020Trading halt or suspensionASX
Response to ASX Query LetterApr 6, 2020Explanation requestASX
Market Update on COVID-19Mar 27, 2020Other filingsASX
Appendix 4D, Half Year Accounts and PresentationFeb 26, 2020Interim reportASX
Cellmids Evolis Patent to be Granted in ChinaFeb 3, 2020Other filingsASX
Appendix 4C and Notes to Appendix 4CJan 29, 2020Quarterly reportASX
Key Midkine Antibody Patents Granted in the US and EuropeJan 5, 2020Other filingsASX
Cellmid Reports on QVC SalesDec 5, 2019Other filingsASX
Cellmid Signs Trading Agreement With API/PricelineNov 5, 2019Other filingsASX
New TV Shopping Agreement for EvolisOct 13, 2019Other filingsASX
New Evolis Distribution & Supply Agreements - China & EuropeOct 1, 2019Other filingsASX
FY2019 Financial ResultsAug 28, 2019ResultsASX
Patent for Improved Midkine Antibody Allowed in EuropeAug 22, 2019Other filingsASX
CDY Signs Distribution Agreement for EVOLIS in South KoreaAug 5, 2019Other filingsASX
Response to Appendix 4C QueryAug 1, 2019Quarterly reportASX
Cellmid Sets Another Sales Record in Q4 FY2019Jul 4, 2019Other filingsASX
Cellmids Evolis Registered in European Union (EU)Apr 30, 2019Other filingsASX
Minimum Holding Share Buy-BackMar 18, 2019Treasury share statusASX
Appendix 4D, Half Year Accounts and Strategy UpdateFeb 21, 2019Interim reportASX
Significant New Findings Published on MidkineFeb 7, 2019Other filingsASX
Cellmid Expects Record Sales in Q2 FY2019Dec 11, 2018Other filingsASX
Cellmid Appoints Exclusive New Zealand DistributorNov 18, 2018Other filingsASX
New Patents for Midkine Antibodies in USA and EuropeNov 6, 2018Other filingsASX
Ikon Legal Action - DecisionNov 2, 2018Other filingsASX
Cellmids Evolis Successfully Launched in USA storesOct 31, 2018Other filingsASX
Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018Other filingsASX
Lead Antibody Effective in Rare Chronic Kidney DiseaseSep 12, 2018Other filingsASX
Cellmid Share Purchase Plan CompletionSep 2, 2018FinancingASX
Evolis USA Distribution UpdateAug 30, 2018Other filingsASX
Preliminary Final ReportAug 24, 2018ResultsASX
Cleansing Notice and Appendix 3BAug 6, 2018FinancingASX
Cellmid Share Purchase PlanJul 31, 2018FinancingASX
Cellmid Share Placement Raises $9MJul 30, 2018FinancingASX
CELLMID UPDATES ON DISTRIBUTION OF EVOLISJul 10, 2018Other filingsASX
CELLMID TO COMMENCE SELLING OF EVOLIS INTO CHINESE MARKETMay 2, 2018Other filingsASX
CELLMID SECURES BLOOMINGDALES USA PARTNERSHIP FOR EVOLISApr 23, 2018Other filingsASX
Appendix 4C - quarterlyApr 22, 2018Quarterly reportASX
CELLMID SIGNS DISTRIBUTION AGREEMENT FOR FILLERINAApr 4, 2018Other filingsASX
Appendix 4D and Half Year AccountsFeb 21, 2018Interim reportASX
RECORD 2M SALES FOR CELLMID FGF5 INHIBITORSJan 9, 2018Other filingsASX
CELLMID QUARTERLY OPERATIONAL UPDATEJan 8, 2018Other filingsASX
CELLMID PLACEMENT TO STRATEGIC INVESTORDec 15, 2017FinancingASX
CELLMID SECURES NEW US RETAIL PARTNER FOR EVOLISDec 6, 2017Other filingsASX
CELLMID OPENS FIRST CONCEPT STORE IN TOKYOOct 25, 2017Other filingsASX
PROPOSED CONSOLIDATION OF SECURITIESOct 23, 2017Other filingsASX
CELLMID RECEIVES $947K R&D TAX CREDITOct 2, 2017Other filingsASX
CELLMID COMPLETES US CONSUMER STUDYAug 20, 2017Other filingsASX
CELLMID SECURES PREMIUM US RETAIL CHANNEL FOR EVOLISAug 2, 2017Other filingsASX
Nature Paper MK in MelanomaJul 3, 2017Other filingsASX
CELLMIDS FGF5 INHIBITOR CLINICAL STUDY PUBLISHEDMar 2, 2017Other filingsASX
Cellmid to Refinance R&D Loan FacilityMar 1, 2017Other filingsASX
MIDKINE ALOPECIA PATENT EUROPEAN ALLOWANCEFeb 6, 2017Other filingsASX
CELLMIDS USA MIDKINE PATENT FOR ALOPECIA ALLOWEDJan 30, 2017Other filingsASX
Appendix 4CJan 23, 2017Quarterly reportASX
CELLMID RECEIVES AUSTRALIAN GOVT GRANT FOR MIDKINE PROGRAMMEJan 18, 2017Other filingsASX
Cellmid Updates on CxBladder LicenseDec 12, 2016Other filingsASX
Cellmid receives 831K R&D tax creditNov 29, 2016Other filingsASX
USA launch of evolisNov 2, 2016Other filingsASX
ASX Market Release - ReinstatementOct 31, 2016Other filingsASX
CELLMID RECORDS HIGHEST EVER QUARTERLY SALES FOR EVOLISOct 10, 2016Other filingsASX
Midkine Antibodies Show Anti-Tumor Activity In Brain CancerOct 5, 2016Other filingsASX
European Midkine Patent For Surgical Adhesion AllowedSep 22, 2016Other filingsASX
New Publication for Cellmids Midkine AntibodyAug 9, 2016Other filingsASX
Transcript of Cellmid Investor Briefing CallJul 29, 2016Other filingsASX
CDY: Ikon Legal ActionJul 22, 2016Other filingsASX
USA Distribution Partnership for Cellmids EvolisJul 19, 2016Other filingsASX
MK antibody publication and patent in bone healingJun 24, 2016Other filingsASX
Midkine Strategy UpdateApr 8, 2016Other filingsASX
Response to ASX QueryMar 30, 2016Explanation requestASX
Cellmid to Refinance RnD LoanFeb 26, 2016Other filingsASX
Cellmid receives $1.12M R&D Tax CreditFeb 11, 2016Other filingsASX
Key Antibody Patent Granted in EuropeFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Anagenics Limited’s releases · as of Nov 12, 2026

Common shares
985,450,795
Fully diluted
985,450,795

Fully diluted

LineShares
Common shares985,450,795

Share count over time

CountShares
Nov 22, 2026985,450,795

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Phillip ChristopherNon-Executive Director · Since at least Nov 5, 2026
Sandy BeardChairman · Since at least Nov 4, 2026
Scott GreasleyExecutive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Anagenics Limited.